;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Vesigenurtacel-L: Phase I/II amended

    Heat Biologics Inc. (NASDAQ:HTBX), Chapel Hill, N.C. Product: Vesigenurtacel-L (HS-410) Business: Cancer Molecular target: NA Description: Compound using Heat Biologics Immune Pan-Antigen Cytotoxic Therapy (ImPACT) …

    Published on 8/18/2014
  • Xilonix: Phase III started

    XBiotech Inc., Austin, Texas Product: Xilonix (MABp1) (CV-18C3, T2-18C3, RA-18C3, CA-18C3) Business: Cancer Molecular target: Interleukin-1 (IL-1) alpha Description: Human mAb against IL-1 alpha Indication: Treat …

    Published on 8/18/2014
  • Adipose-derived stem and regenerative cells: Phase II halted

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Adipose-derived stem and regenerative cells (ADRCs) Business: Cardiovascular Molecular target: NA Description: Adipose-derived stem and …

    Published on 8/11/2014
  • AHRO-001: Phase Ib started

    AtheroNova Inc. (OTCBB:AHROD), Irvine, Calif. Maxwell Biotech Group Ltd., Moscow, Russia Product: AHRO-001 Business: Cardiovascular Molecular target: NA Description: Bile salt hyodeoxycholic acid Indication: Treat …

    Published on 8/11/2014
  • Eravacycline: Completed Phase III enrollment

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Product: Eravacycline (TP-434) Business: Infectious Molecular target: NA Description: Broad-spectrum fluorocycline antibiotic Indication: Treat complicated…

    Published on 8/11/2014
  • Fostamatinib disodium: Phase III started

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: Fostamatinib disodium (formerly R788, Tamatinib fosdium) Business: Autoimmune Molecular target: Spleen tyrosine kinase (SYK) Description: …

    Published on 8/11/2014
  • Ganetespib: Phase II/III ongoing

    Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Lexington, Mass. Product: Ganetespib (formerly STA-9090) Business: Cancer Molecular target: Heat shock protein 90 (Hsp90) Description: Small molecule heat shock protein 90 (…

    Published on 8/11/2014
  • GEN-003: Phase II started

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Product: GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell vaccine …

    Published on 8/11/2014
  • Graspa: Phase II started

    Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Graspa (ERY-ASP) Business: Cancer Molecular target: Not applicable Description: L-asparaginase encapsulated in red blood cells Indication: Second-line treatment…

    Published on 8/11/2014
  • Graspa: Phase I/II started

    Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Graspa (ERY-ASP) Business: Cancer Molecular target: Not applicable Description: L-asparaginase encapsulated in red blood cells Indication: Treat acute …

    Published on 8/11/2014
  • ISIS-SMNRx: Phase III start

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 8/11/2014
  • KB001-A: Completed Phase II enrollment

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO), South San Francisco, Calif. Product: KB001-A Business: Infectious Molecular target: NA Description: Humanized antibody fragment against PcrV (V-antigen) on Pseudomonas …

    Published on 8/11/2014
  • Loteprednol etabonate mucosal penetrating particle: Phase II started

    Kala Pharmaceuticals Inc., Waltham, Mass. Product: Loteprednol etabonate mucosal penetrating particle, LE-MPP (KPI-121) Business: Ophthalmic Molecular target: NA Description: Loteprednol etabonate, a steroid, delivered …

    Published on 8/11/2014
  • MM-D37K: Phase I/IIa started

    MetaMax LLC, Moscow, Russia Product: MM-D37K Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (CDK6) Description: Inhibitor of cyclin dependent kinase 4 (CDK4) and CDK6 …

    Published on 8/11/2014
  • MSB0010718C: Phase II started

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: MSB0010718C Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb against programmed cell death 1 …

    Published on 8/11/2014
  • NPSP795: Phase IIa started

    NPS Pharmaceuticals Inc. (NASDAQ:NPSP), Bedminster, N.J. Product: NPSP795, SB-423562 Business: Endocrine/Metabolic Molecular target: Calcium sensing receptor (CaSR) Description: Small molecule antagonist of the calcium …

    Published on 8/11/2014
  • PEGPH20: Phase II resumed

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Product: PEGPH20 (formerly PEGrHuPH20) Business: Cancer Molecular target: Hyaluronan Description: Recombinant human PH20 hyaluronidase enzyme conjugated to …

    Published on 8/11/2014
  • PRT-201: Phase III started

    Proteon Therapeutics Inc., Waltham, Mass. Product: PRT-201 Business: Renal Molecular target: Elastase Description: Recombinant human elastase Indication: Improve arteriovenous fistula (AVF) surgical outcomes in chronic …

    Published on 8/11/2014
  • RSLV-132: Phase II started

    Resolve Therapeutics LLC, Seattle, Wash. Product: RSLV-132 Business: Autoimmune Molecular target: NA Description: Mono-specific nuclease Fc-fusion protein that targets and removes immune complexes which are activating …

    Published on 8/11/2014
  • RXDX-101: Phase I/IIa started

    Ignyta Inc. (NASDAQ:RXDX), San Diego, Calif. Nerviano Medical Sciences s.r.l., Nerviano, Italy Product: RXDX-101 Business: Cancer Molecular target: c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1); Neurotrophic …

    Published on 8/11/2014
  • TKM-Ebola: Phase I ongoing

    Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C. Product: TKM-Ebola (TKM-100201) (formerly Ebola SNALP) Business: Infectious Molecular target: NA Description: Combination of short interfering RNAs (…

    Published on 8/11/2014
  • Ztilido: Clinical trial started

    Scilex Pharmaceuticals Inc., West Chester, Pa. Product: Ztilido Business: Neurology Molecular target: NA Description: Transdermal lidocaine patch formulation Indication: Treat pain associated with post-herpetic …

    Published on 8/11/2014
  • Ampyra: Phase III start

    Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Product: Ampyra ( Fampyra fampridine - EU) dalfampridine (BIIB041) Business…

    Published on 8/4/2014
  • Apatorsen: Phase II started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Product: Apatorsen (OGX-427) Business: Cancer Molecular target: Heat shock protein 27 (Hsp27) …

    Published on 8/4/2014
  • ATryn: Phase III started

    LFB S.A., Les Ulis, France rEVO Biologics Inc., Framingham, Mass. Product: ATryn Business: Genitourinary Molecular target: Not available Description: Recombinant human antithrombin (rhAT) Indication: Treat early-onset …

    Published on 8/4/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993